Current Trials
| ECHO Open to Acrrual Clinical Trials Updated: 6/24/20 Bladder / Urothelial Muscle Invasive Alliance A031701 A Phase II study of Dose-Dense Gemcitabine plus Cisplatin (DDGC) in patients with Muscle-Invasive Bladder Cancer with Bladder preservation for those patients whose tumors harbor deleterious DNA Damage Response (DDR) Gene alterations SGTN22E-003 / EV-302 An open-label, randomized, controlled phase 3 study of Enfortumab Vedotin in combination with Pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer. Breast Cancer CLEE011O12301C (TRIO033 – NATALEE) A Phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of Ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant Trial with Ribociclib [LEE011]: NATALEE) Metastatic DS8201-A-U303 A phase 3, multicenter, randomized, open-label, active-controlled trial of DS-8201A, an anti-her2-antibody drug conjugate (ADC), versus treatment of physician’s choice for HER2 low, unresectable and/or metastatic breast cancer subjects Colorectal Metastatic NRG-GI004 / SWOG-S1610 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6 / Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer Lung ARRAY-818-202 A Phase II, Open-Label Study of Encorafenib + Binimetinib in Patients with BRAFv600E-Mutant Non-Small Cell Lung Cancer Alchemist Trials Adjuvant Trials for completely resected patients EGFR or ALK positive A151216 Adjuvant Lung Cancer enrichment marker identification and sequencing trial (Alchemist) A081105 Randomized double blind Placebo controlled study of Erlotinib or Placebo in patients with completely resected Epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) E4512 A phase III double-blind trial for surgically resected early stage Non-Small Cell Lung cancer: Crizotinib versus Placebo for patients with tumors harboring the Anaplastic Lymphoma Kinase (ALK) fusion protein First Line Metastatic MS200647-0037 A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bifunctional fusion protein PDL-1 antibody + TGFβ neutralizing trap) versus Pembrolizumab as a First-line treatment in Patients with PD-L1 Expressing Advanced Non-Small Cell Lung Cancer TAK-788-3001 A Randomized Phase 3 Multicenter Open-Label Study to compare the efficacy of TAK-788 as first-line treatment versus Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Second Line Metastatic: Mirati MRT516-005 A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression on or after Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy Melanoma ECOG EA6134 Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma Prostate Cancer LAE201INT2101 – *****On Hold**** A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone plus Afuresertib in Patients with Metastatic Castration-Resistant Prostate Cancer Following Standard of Care Treatment NRG-GU002 A Phase II-III trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel Rectal Cancer Neoadjuvant NRG-GI002 ***Temporarily closed to Accrual*** A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer N1048 / RTOG 1271 A Phase II/III trial of Neoadjuvant FOLFOX, with Selective use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision Renal Cell EA8143 A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) Solid Tumors SGNLVA-005 Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors Screening Lung Screening I-ELCAP International Early Lung Cancer Action Program: Enrollment and Screening Protocol Supportive Care Amgen Protocol 20170758 Neulasta Onpro *****On Hold**** A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects with Non-Myeloid Malignancies at High Risk for FN and Receiving Neulasta (Pegfilgrastim) Onpro kit or other Physician Choice Options for Prophylaxis of FN CADEX-0001 – ***On Hold*** Development and Validation of a Multiplex qPCR Short Fragment Cell Free DNA Assay as a Potential Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer Ready 1 / CUSA-081-HEM-01 /YYA36723 Phase 3, Randomized, Double-Hem-Blind, Active and Placebo Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs) ES2018-01 Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors Seer – 020102 (SeerPro) A Prospective Blood Sample Collection Study to Evaluate a Panel of Protein-based Biomarkers |
For more information on clinical trials, please contact research@echoassociates.org.